Document Type
Article
Publication Date
2-25-2022
Abstract
Despite the lack of approved anti-angiogenic therapies in squamous cell carcinoma of the head and neck (SCCHN), preclinical and more recent clinical evidence support the role of targeting the vascular endothelial growth factor (VEGF) in this disease. Targeting VEGF has gained even greater interest following the recent evidence supporting the role of immunotherapy in the management of advanced SCCHN. Preclinical evidence strongly suggests that VEGF plays a role in promoting the growth and progression of SCCHN, and clinical evidence exists as to the value of combining this strategy with immunotherapeutic agents. Close to 90% of SCCHNs express VEGF, which has been correlated with a worse clinical prognosis and an increased resistance to chemotherapeutic agents. As immunotherapy is currently at the forefront of the management of advanced SCCHN, revisiting the rationale for targeting angiogenesis in this disease has become an even more attractive proposition.
Recommended Citation
Saba, Nabil; Vijayvargiya, Pooja; Vermorken, Jan; Rodrigo, Juan; Willems, Stefan; Zidar, Nina; de Bree, Remco; Mäkitie, Antti; Wolf, Greg; Argiris, Athanassios; Teng, Yong; and Ferlito, Alfio, "Targeting Angiogenesis in Squamous Cell Carcinoma of the Head and Neck: Opportunities in the Immunotherapy Era" (2022). Department of Medical Oncology Faculty Papers. Paper 177.
https://jdc.jefferson.edu/medoncfp/177
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Language
English
Comments
This article is the author’s final published version in Cancers, Volume 14, Issue 5, February 2022, Article number 1202.
The published version is available at https://doi.org/10.3390/cancers14051202. Copyright © Saba et al.